Literature DB >> 30570459

Why We Should Defend Gene Editing as Eugenics.

Nicholas Agar.   

Abstract

This paper considers the relevance of the concept of "eugenics,"-a term associated with some of the most egregious crimes of the twentieth century-to the possibility of editing human genomes. The author identifies some uses of gene editing as eugenics but proposes that this identification does not suffice to condemn them. He proposes that we should distinguish between "morally wrong" practices, which should be condemned, and "morally problematic" practices that call for solutions, and he suggests that eugenic uses of gene editing fall into this latter category. Although when we choose the characteristics of future people we are engaging in morally dangerous acts, some interventions in human heredity should nevertheless be acknowledged as morally good. These morally good eugenic interventions include some uses of preimplantation genetic diagnosis. The author argues that we should think about eugenic interventions in the same way that we think about morally problematic interventions in public health. When we recognize some uses of gene editing as eugenics, we make the dangers of selecting or modifying human genetic material explicit.

Entities:  

Keywords:  eugenics; gene editing; moral marketing; morally problematic practice; morally wrong practice; preimplantation genetic diagnosis

Mesh:

Year:  2019        PMID: 30570459     DOI: 10.1017/S0963180118000336

Source DB:  PubMed          Journal:  Camb Q Healthc Ethics        ISSN: 0963-1801            Impact factor:   1.284


  2 in total

1.  Lives Not Worth Living in Modern Euthanasia Regimes.

Authors:  Scott Kim
Journal:  J Policy Pract Intellect Disabil       Date:  2019-06-27

2.  Is selecting better than modifying? An investigation of arguments against germline gene editing as compared to preimplantation genetic diagnosis.

Authors:  Alix Lenia V Hammerstein; Matthias Eggel; Nikola Biller-Andorno
Journal:  BMC Med Ethics       Date:  2019-11-21       Impact factor: 2.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.